Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com

Please find enclosed a Press Release on "Dr.

Reddy's Laboratories Limited announces filing of Annual Report on Form 20-F."

This is for your information.

CC:- New York Stock Exchange Inc.(Stock Code :RDY)

Laboratories announces filing of

India, June 30, 2021: Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC:

DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")

today announced that its Annual Report on Form 20-F containing its consolidated financial statements for the fiscal year ended

March 31, 2021 and prepared in accordance with the International Financial Reporting Standards (IFRS) as issued by the International

Accounting Standards Board was filed with the United States Securities and Exchange Commission (SEC) on June 30, 2021.

on Form 20-F is also available on the website of Dr. Reddy's, www.drreddys.com. American Depositary Receipts (ADRs)

holders may also obtain a hard copy of the Annual Report on Form 20-F at no cost, by sending a written request to the Company's

registered office or by sending an e-mail to shares@drreddys.com.

Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated

pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses

- Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers

a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated

formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management

and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include - USA, India, Russia

& CIS countries, and Europe. For more information, log on to: www.drreddys.com.

This press release may include statements of future expectations and other forward-looking statements that are based on the management's

current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance

or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking

by reason of context, the words "may", "will", "should", "expects", "plans",

"intends", "anticipates", "believes", "estimates", "predicts", "potential",

or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may

differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance

of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of

insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive

factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions

or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets

addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics,

pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified

in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and

"Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2021. The company

assumes no obligation to update any information contained herein."